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Abstract
Background: Proton pump inhibitors are among the most 
frequently prescribed drugs in the world and are generally 
considered safe. However, there is growing concern regard-
ing their safety. Summary: A nonsystematic review of the 
current literature was performed regarding proton pump in-
hibitors and their adverse effects. Proton pump inhibitors 
seem to be associated with fundic gland polyp development 
(without clinical relevance) and Clostridium difficile infection. 
Also, in cirrhotic patients, their prescription should be care-
fully reviewed. Regarding their association with other enter-
ic infections, micronutrient deficiency, dementia, and chron-
ic kidney disease, current evidence is still of low quality, and 
further studies are needed. Key Messages: Considering the 
current evidence, most patients with a clear clinical indica-
tion for proton pump inhibitor treatment should probably 
benefit from the maintenance of their treatment without 
significant adverse effects. However, higher-quality studies 
are needed to confirm or dismiss most of the proposed ad-
verse effects. © 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
Introdução: Os inibidores da bomba de protões estão en-
tre dos fármacos mais utilizados a nível mundial e global-
mente considerados seguros. Contudo, evidência recente 
tem levantado dúvidas sobre o seu perfil de segurança. 
Sumário: Efetuada uma revisão não-sistemática da litera-
tura relativamente aos inibidores da bomba de protões e 
seus efeitos adversos. Os inibidores da bomba de protões 
parecem associar-se significativamente com o desen-
volvimento de pólipos das glândulas fûndicas (sem sig-
nificado clínico) e com a infeção por Clostridium difficile. 
Além disso, em doentes cirróticos a sua prescrição deve 
ser cuidadosamente revista. A sua associação com outras 
infeções entéricas, défice de micronutrientes, demência e 
doença renal crónica provêm de evidência de baixa quali-
dade e mais estudos são necessários. Mensagens chave: 
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Xavier/Magalhães/CotterGE Port J Gastroenterol2
DOI: 10.1159/000487154
Tendo em conta a evidência atual, a maioria dos doentes 
com indicação para terapêutica com inibidores da bomba 
de protões podem beneficar da sua manutenção sem 
efeitos adversos significativos. Contudo, estudos de mel-
hor qualidade são necessários para confirmar ou desmen-
tir a maioria dos efeitos secundários propostos.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Proton pump inhibitors (PPIs) have been available 
since 1989, when the first drug of this class, omeprazole, 
was released. They are currently one of the most frequent-
ly prescribed drugs [1] and are available for “over-the-
counter” acquisition in several countries. 
They decrease acid production by irreversible block-
age of H+/K+-adenosine triphosphatase that is present on 
gastric parietal cells and are currently the treatment of 
choice in several clinical conditions, such as symptom-
atic and complicated gastroesophageal reflux disease 
(GERD), Zollinger-Ellison syndrome, prevention of ul-
cers in nonsteroidal anti-inflammatory drug (NSAID) 
users, induction of peptic ulcer healing, and even in the 
eradication of Helicobacter pylori.
In symptomatic GERD, PPIs are capable of controlling 
symptoms in a higher percentage of patients than hista-
mine 2 receptor (H2R) antagonists, and in patients with 
erosive GERD, this class of drugs is superior to placebo, 
H2R, and sucralfate in inducing healing [2]. PPI use in 
patients with Barrett esophagus is also associated with a 
decreased risk of progression to neoplastic Barrett esoph-
agus, compared to H2R antagonists or no acid suppres-
sive therapy, and is currently recommended as chemo-
prophylaxis in this group of patients [3].
There are several conditions for which NSAIDs are the 
mainstay of treatment. However, these drugs are associ-
ated with morbidity and even mortality, mainly due to 
gastrointestinal (GI) side effects that can range from a 
simple erosion to an ulcer complicated by bleeding or 
perforation [4]. In patients under NSAIDs, PPIs are effec-
tive in the prevention of gastric and duodenal ulcers, are 
superior to placebo and H2R antagonists, and are not as-
sociated with the GI side effects reported in misoprostol 
users [4].
PPIs are also effective in the induction of peptic ulcer 
healing and in patients with ulcers with a high risk of 
bleeding; PPI infusion therapy is associated with a re-
duced risk of rebleeding, surgery, and mortality [5]. Also, 
PPIs are included in every treatment scheme for H. py-
lori eradication, since they have themselves a weak anti-
bacterial effect and are capable of stabilizing and raising 
the antibacterial effects of the antibiotics [6].
They are generally considered safe and are associated 
with mild side effects; however, there is growing concern 
regarding their safety. In this review, we will discuss the 
proposed mechanisms by which PPIs may induce ad-
verse effects, evaluate the current evidence, and summa-
rize current recommendations (Table 1). To help in the 
interpretation of the current evidence, we will also re-
port, when available, the application of Hill criteria [7]. 
These include 9 parameters (strength of association, con-
sistency, specificity, temporality, biological gradient, bi-
ological plausibility, coherence, experiment, and analo-
gy) and try to differentiate between causality and asso-
ciation [8].
Methods
A nonsystematic review of the current literature was per-
formed regarding PPIs and their adverse effects. We performed 
a bibliographic search on PubMed/Medline (http://www.ncbi.
nlm.nih.gov/pubmed/) using the following keywords: “proton 
pump inhibitors”; “risks”; and “adverse effects.” Only articles 
written in English were reviewed. Data collected from systematic 
reviews, meta-analyses, and guidelines/position statements pub-
lished in the last 10 years were preferred; however, when there 
was a lack of information in this time period, we used older pub-
lications.
Proposed Side Effects of PPIs
Infections
Several works have published articles regarding PPI 
use and their association with increased infection risk. 
Gastric acid secretion is part of the local defense system 
against ingested pathogens and is also determinant of the 
composition of the GI flora. PPI-induced hypochlorhy-
dria seems capable of altering GI microbiota and is, there-
fore, predisposing patients to GI infections [9].
Clostridium difficile Infection
Clostridium difficile is a gram-positive spore-forming 
bacterium, and intestinal colonization by this agent is fa-
cilitated by disruption of commensal microbiota, as de-
scribed in patients treated with PPIs. In fact, studies per-
formed in healthy volunteers showed that after only 4–8 
weeks of high-dose PPI, there were increased bacterial 
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Table 1. Summary of adverse effects, proposed causality, current evidence, estimated relative risk, and recommendations
Adverse effect Proposed causality Current evidence Relative risk Recommendations of experts/
societies
CDI Disruption of commensal microbiota 
[10]
Apparently, association with 
both primary and recurrent 
infection
Only a moderate effect 
compared to other risk factors
Up to 3-fold 
increase [7]
Use with caution in patients with risk 
factor for developing CDI infection 
(hospitalized or living in nursing 
facilities, elderly patients, 
immunodeficient patients, and those 
exposed to patients with CDI) [14, 
15]
Salmonella and 
Campylobacter 
infection
Disruption of commensal microbiota Literature with conflicting 
results
Need for higher-quality studies
2- to 6-fold 
increase [7]
–
Spontaneous 
bacterial peritonitis
Disruption of commensal microbiota 
[20]
Literature with conflicting 
results 
Need for higher-quality studies
Up to 3-fold 
increase [7]
Review PPI prescription in cirrhotic 
patients 
Few conditions benefit from PPI 
treatment in these patients [15, 24]
Pneumonia Disruption of commensal microbiota 
[25]
No association with PPI intake 
Possible protopathic bias
– –
Fundic gland 
polyps
Uncertain
Fundic gland cysts are caused by 
mucus blocking of the fundic pits 
[29]
Clear association between PPI 
intake and their development
No clinical relevance associated 
with their raised incidence
OR 9.00 [30] –
Gastrointestinal 
malignancy
Bacterial growth and nitrosamine 
formation [32]
PPI-induced hypergastrinemia is a 
possible risk factor for gastric 
carcinoma and type 1 and 2 
neuroendocrine tumors of the 
stomach [33]
In Helicobacter pylori-infected 
patients, PPI leads to a corpus-
predominant pangastritis [34]
No association with PPI intake – –
Clopidogrel 
interaction and 
myocardial 
infarction
CYP450 metabolism competition
Blockage of vascular nitric oxide 
synthase [40]
No clear association with PPI 
intake
– –
Vitamin B12 
deficiency
Malabsorption [43] Literature with conflicting 
results
Need for higher-quality studies
60–70% 
increase [7]
Recommendation against reposition/
monitoring [44]
Iron deficiency Malabsorption [46] Low-quality evidence
Need for higher-quality studies
– Recommendation against monitoring 
[14]
Calcium deficiency Malabsorption [48] Literature with conflicting 
results
Need for higher-quality studies
– Recommendation against reposition 
[44]
Osteoporosis Calcium malabsorption
Interference with bone metabolism 
[51]
Literature with conflicting 
results
Need for higher-quality studies
Up to 4-fold 
increase [7]
Recommendation against monitoring 
bone mineral density [44] 
Dementia Vitamin B12 deficiency
Increased production of β-amyloid 
[55, 56]
Literature with conflicting 
results and low-quality 
evidence
Need for higher-quality studies
4–80% 
increase [7]
–
Kidney disease AIN: idiosyncratic
Chronic kidney disease: recurrent 
AIN [62] 
Low-quality evidence
Need for higher-quality studies
10–20% 
increase [7]
Recommendation against monitoring 
creatinine [44]
CDI, Clostridium difficile infection; PPI, proton pump inhibitor; OR, odds ratio; AIN, acute interstitial nephritis.
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taxa associated with C. difficile in stools [10]. A meta-
analysis of 50 controlled observational studies showed a 
significant association between acid suppressant therapy 
use and risk of developing C. difficile infection (CDI) 
(odds ratio [OR] 1.26) [11]. Also, a systematic review and 
meta-analysis of 16 observational studies showed that pa-
tients under PPI therapy had an increased risk of recur-
rent CDI with an OR of 1.52, even after adjustment for 
age and other potential confounders [12]. Even though 
the current evidence seems consensual in establishing an 
association between PPI use and CDI, the risk associated 
with PPIs is only modest when compared to other drugs, 
like antibiotics [13]. Evaluating Hill criteria, the current 
evidence has a moderate strength, and both temporality 
and plausibility are present; however, other criteria have 
not been established yet [7].
Both experts and national gastroenterology societies 
reinforce the need to review PPI dose and treatment du-
ration in patients with risk factors for CDI, including 
those hospitalized or living in nursing facilities, elderly 
patients, immunodeficient patients, and those exposed to 
patients with CDI [14, 15]. 
Campylobacter and Salmonella Infection
GI microbiota alterations induced by PPI use may pre-
dispose patients to infections with pathogens other than 
C. difficile, particularly Salmonella and Campylobacter. 
Regarding this topic, the literature is less consensual. 
Garcia Rodriguez et al. [16] found a significant associa-
tion between PPI use and increased risk of bacterial gas-
troenteritis compared to nonuse, regardless of the treat-
ment duration (relative risk [RR] 2.9), and this risk was 
further increased with the double dose (RR 5.0). Also, a 
systematic review including 6 studies assessing enteric in-
fection risk in PPI users identified an increased risk of 
such infections in patients under acid suppressant agents 
(OR 2.55) [17]. On the other hand, a retrospective analy-
sis of almost 2 million patients, of which over 350,000 
were under PPI treatment, found that PPI users had 3.1- 
to 6.9-fold higher rates of Campylobacter and Salmonella 
infections even before PPI prescription [18]. Another 
study assessing the safety of PPI treatment, including data 
from 2 controlled randomized clinical trials, with 12- and 
5-year follow-up, was not able to find significant differ-
ences between users and nonusers regarding enteric in-
fections [19]. Evaluating Hill criteria, the current evi-
dence has a moderate strength, and temporality, consis-
tency, biological gradient, plausibility, and analogy are 
present; however, other criteria have not been established 
yet [7].
Spontaneous Bacterial Peritonitis 
Spontaneous bacterial peritonitis (SBP) is one possible 
complication of cirrhosis, and an alteration in intestinal 
wall permeability seems to play a role in the pathogenesis 
of this condition [20]. As described before, PPIs can in-
duce GI microbiota alterations and promote the over-
growth of pathogenic agents. A recently published meta-
analysis found an increased risk of SBP in PPI users when 
compared to nonusers (hazard ratio [HR] 1.72) [21], and 
these findings were similar to those reported previously 
by Xu et al. [22] who also found an increased risk of SBP 
in this population (OR 2.13). However, not all authors 
report an increased risk of SBP in PPI users, and a meta-
analysis including 10 case-control and 6 cohort studies 
found that the association of PPIs with SBP was only ob-
served in case-control studies (OR 2.97) and did not find 
an association between PPI intake and in-stay and 30-day 
mortality [23]. Evaluating Hill criteria, the current evi-
dence has a weak strength, and only temporality and 
plausibility are present [7].
Despite conflicting reports in the literature, several na-
tional gastroenterology societies reinforce the need to re-
view PPI prescription in cirrhotic patients, particularly 
because few conditions showed evidence of benefit with 
these drugs [15, 24]. 
Pneumonia
Community-acquired pneumonia (CAP) is another 
infectious complication associated with PPI use in some 
studies. The proposed mechanism is that PPI-induced 
upper GI bacterial overgrowth can predispose to respira-
tory infections through potential micro-aspirations or 
translocation to the lung [25]. 
A large meta-analysis including 26 studies and 200,000 
patients found an increased risk of 1.49 for CAP with PPI 
therapy, regardless of PPI dose or patient age, and these 
patients also had an increased risk for hospitalization due 
to CAP (OR 1.61) [26]. Interestingly, the authors found 
that treatment with a PPI for less than 1 month was as-
sociated with the highest risk of CAP (OR 2.10), and such 
risk decreased and lost statistical significance as the dura-
tion of PPI therapy increased. Actually, another study 
found that the risk for CAP was limited to patients start-
ing PPI within the last 30 days and that this risk increased 
progressively with a shorter duration of treatment, reach-
ing an OR of 6.53 when it was started in the 2 days before 
CAP diagnosis [25]. These results led some authors to 
propose that the association between PPI use and CAP is 
a result of a protopathic bias, which occurs when a drug 
is used to treat an early sign of the outcome, creating the 
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appearance that it is actually associated with the outcome 
[7].
Also, other studies have not been able to find such an 
association between PPI and CAP, including a random-
ized, double-blinded, placebo-controlled trial designed to 
assess esomeprazole efficacy in the prophylaxis of peptic 
ulcers in patients under low-dose acetylsalicylic acid (the 
OBERON study), which found similar rates of pneumo-
nia in patients under PPI and placebo [27]. Evaluating 
Hill criteria, the current evidence has a weak strength, 
and only plausibility is present [7].
GI Malignancy
Fundic Gland Polyps 
Fundic gland polyp (FGP) development has long been 
associated with PPI use. They are found in up to 23% of 
endoscopies, and dysplasia is found in < 1% of these pol-
yps [28]. The mechanism involved in the increased prev-
alence of FGP in PPI users is still uncertain, but one hy-
pothesis is that fundic gland cysts are caused by mucus 
blocking of the fundic pits [29].
A prospective study assessing 1,780 patients undergo-
ing upper gastroduodenal endoscopy concluded that PPI 
use for over 12 months was a risk factor for FGP develop-
ment with an OR of 9.00, and none of the polyps was 
found to have dysplasia [30]. This raised incidence of 
FGPs is not associated with clinical relevance, as a study 
including over 100,000 patients found that these polyps 
seemed to inversely correlate with gastric neoplasia [31]. 
According to Hill criteria, this is the only adverse side ef-
fect regarding which the current evidence has a high 
strength, and temporality, consistency, specificity, plau-
sibility, and experiment are present [7].
Gastric Malignancy
Other authors have raised concern regarding a possi-
ble association between PPI intake and gastric cancer. 
This potential adverse effect has several proposed mecha-
nisms [32]. PPIs suppress gastric acid secretion and may 
interfere with bacterial growth and nitrosamine forma-
tion. Also, the reduction of gastric acid secretion can lead 
to hypergastrinemia, which has been identified as a pos-
sible risk factor for gastric carcinoma and type 1 and 2 
neuroendocrine tumors of the stomach [33]. In addition, 
in patients with H. pylori infection, PPI-induced hypo-
chlorhydria leads to a shift from a gastritis confined to the 
antrum to a corpus-predominant pangastritis [34].
A meta-analysis of 11 observational studies concluded 
that both PPI treatment and H2R antagonists were asso-
ciated with an increased risk of gastric cancer, even 
though the authors were not able to assess the effect of 
underlying gastric conditions, such as H. pylori infection 
[32]. However, an FDA-mandated study was not able to 
find an increased incidence of either gastric or any other 
GI malignancy in patients under PPI treatment [35], and 
a Cochrane Database systematic review concluded that, 
currently, there is no clear evidence that long-term use of 
PPIs can cause or accelerate the progression of corpus 
gastric atrophy or intestinal metaplasia, and no partici-
pant in the included studies showed any dysplastic or 
neoplastic changes [36]. Also, 2 studies aimed to assess 
the long-term safety of PPI under controlled randomized 
clinical trial conditions (LOTUS and SOPRAN studies) 
found no gastric carcinoids or adenocarcinomas in pa-
tients during their course [19].
Despite the fact that the current evidence does not sup-
port a clear association between PPI treatment and gastric 
malignancy, patients with a clinical indication for long-
term PPI treatment should be tested and, when positive, 
treated for H. Pylori infection in order to prevent a pro-
gression of gastritis [34].
Clopidogrel Interaction and Myocardial Infarction
Clopidogrel, an antiplatelet drug, is an inactive pro-
drug that needs to be activated by cytochrome P450. Since 
PPIs are also primarily metabolized by this cytochrome, 
there has been concern that PPIs may decrease clopido-
grel efficacy through a competitive metabolism effect. 
A retrospective cohort study of 8,205 patients taking 
clopidogrel after hospitalization for an acute coronary 
syndrome found that use of clopidogrel plus PPI was as-
sociated with an increased risk of death or rehospitaliza-
tion compared to use of clopidogrel alone (OR 1.25) [37]. 
However, the COGENT study, a randomized controlled 
trial in which patients were given either clopidogrel + PPI 
or clopidogrel + placebo, found similar rates of cardiovas-
cular events in the 2 groups (HR 0.99) [38]. A recently 
published systematic review and meta-analysis including 
30 observational studies and 4 randomized controlled tri-
als reported very interesting findings [39]. The study 
found higher rates of all-cause mortality, nonfatal myo-
cardial infarction, stroke, revascularization, and stent 
thrombosis in patients receiving PPIs plus clopidogrel 
when compared to patients receiving clopidogrel alone. 
However, when assessing only the data from randomized 
controlled trials, no differences were found regarding 
ischemic outcomes. Considering this sub-analysis, the 
authors concluded that observational studies may include 
several biases responsible for the differences in the re-
sults. 
Xavier/Magalhães/CotterGE Port J Gastroenterol6
DOI: 10.1159/000487154
Besides an interaction with clopidogrel, other authors 
proposed a different mechanism through which PPIs 
could increase the risk of myocardial infarction. This is 
based on the ex vivo finding that PPIs can directly block 
vascular nitric oxide synthase, therefore promoting vas-
cular contraction [40]. A recent publication assessing a 
general population found GERD patients exposed to PPIs 
to have a 1.16-fold increased association with myocardial 
infarction, and this association existed regardless of clop-
idogrel use [41]. This association had previously been 
proposed during the SOPRAN trial, in which the omepra-
zole group had more reports of myocardial infarction 
[19]. However, the FDA assessed the available evidence 
and concluded that the differences reported do probably 
not indicate the presence of a true effect; therefore, the 
long-term use of these drugs is not likely to be associated 
with an increased risk of heart problems [42].
According to Hill criteria, the current evidence regard-
ing both clopidogrel interaction and myocardial infarc-
tion risk has a weak strength, and only temporality and 
plausibility criteria are present [7].
Micronutrient Deficiencies
Vitamin B12
Vitamin B12 requires the presence of gastric acid and 
pepsin to be released from dietary proteins and become 
able to proceed with the complex process that leads to its 
absorption in the GI tract. Consequently, PPIs can theo-
retically lead to vitamin B12 malabsorption; however, 
conflicting results have been published. A case-control 
study performed in patients with an incident diagnosis of 
B12 deficiency found both PPI and H2R antagonists use 
for over 2 years to be associated with an increased risk of 
vitamin B12 deficiency (OR 1.65 and 1.25, respectively) 
[43]. However, another case-control study performed in 
patients over 65 years of age was not able to find a differ-
ence in vitamin B12 levels between users and nonusers of 
PPIs, nor between their mean corpuscular volume or ho-
mocysteine levels [44].
Considering the current evidence, a Best Practice Ad-
vice issued in 2017 by the American Gastroenterology As-
sociation recommends against routine monitoring or 
raised intake of vitamin B12 in patients under PPIs [45].
Iron
As for vitamin B12, dietary iron absorption seems to be 
facilitated by gastric acid, and therefore, PPIs can theo-
retically lead to iron malabsorption. A retrospective study 
trying to assess the effect of PPI use on iron deficiency 
anemia concluded that the use of PPIs for over 1 year was 
associated with lower hemoglobin, hematocrit, and mean 
corpuscular volume compared to nonuse [46]. Another 
study performed in patients with hemochromatosis con-
cluded that PPI use reduced the need for phlebotomies 
and that PPI intake could reduce the absorption of iron 
from a regular meal [47]. However, a previous study in-
cluding over 100 patients with Zollinger-Ellison syn-
drome under PPI therapy for a mean of 5.7 years was not 
able to find a decrease in iron stores in these patients [48]. 
Even though these results should raise our attention, 
current evidence is provided by small-sampled studies 
providing low-quality evidence, and experts recommend 
against the routine investigation of anemia in patients on 
PPIs [14].
Calcium
Calcium absorption seems to be influenced by gastric 
pH, and in vitro studies show that increased pH reduces 
calcium absorption, leading to the assumption that PPIs 
can reduce calcium absorption [49]. A randomized pla-
cebo-controlled study reported that with only a 1-week 
course of PPI, elderly women had a significant decrease 
in fractional calcium absorption under fasting conditions 
[49]. However, another study performed in postmeno-
pausal women was not able to find differences in frac-
tional calcium absorption before and after 30 days of PPI 
use [50], and also other authors have reported that gastric 
pH alterations are not enough to impair GI calcium ab-
sorption [51].
Considering the current evidence, a Best Practice Ad-
vice issued in 2017 by the American Gastroenterology As-
sociation recommends against routine raised intake of 
calcium in patients under PPIs [45].
Bone Fracture and Osteoporosis
An association between PPI use and bone fractures 
was also suggested. The mechanisms included not only 
the malabsorption of calcium, but also an interference 
with bone metabolism caused by the hyperparathyroid-
ism seen in patients with hypergastrinemia. 
A systematic review and meta-analysis of 18 observa-
tional studies concluded that PPI intake modestly in-
creased the risk of hip (RR 1.26), spine (RR 1.58), and 
any-site fracture (RR 1.33), with similar risks for patients 
using PPI for under or over 1 year [52]. The authors, how-
ever, admitted that their results could have been influ-
enced by cofounders and bias associated with the obser-
vational studies included in the meta-analysis. 
Studies assessing bone mass showed conflicting re-
sults. Maggio et al. [53] assessed cortical and trabecular 
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bone mineral density (BMD) and cross-sectional area and 
concluded that PPI users showed lower trabecular BMD 
than nonusers, even after age and gender adjustments. 
However, another study assessing not only areal BMD 
but also changes in bone structure which would predis-
pose to fractures in the absence of changes in BMD con-
cluded that long-term PPI use was not associated with 
changes in BMD or bone structure that would predispose 
to bone fractures [54]. Reviewing Hill criteria, the current 
evidence regarding bone fracture risk in PPI users has a 
weak strength, and only temporality and plausibility are 
present [7].
Considering the current evidence, a Best Practice Ad-
vice issued in 2017 by the American Gastroenterology As-
sociation recommends against routine monitoring of 
BMD in patients under PPIs [45], and the FDA also de-
termined that an osteoporosis and fracture warning on 
PPI treatment was not indicated [55]. 
Dementia
PPIs have 2 proposed mechanisms contributing to de-
mentia. The first is the proposed association between 
PPIs and a reduction in vitamin B12, which can contribute 
to a decreased cognitive function. The second is based on 
the observation that PPI treatment enhances the produc-
tion of β-amyloid, a key event in the pathogenesis of Alz-
heimer disease. PPIs lead to increased production of sev-
eral isoforms of β-amyloid in mouse brains [56], and 
these may be due to a direct PPI modulation of 2 protease 
enzymes responsible for cleavage of amyloid precursor 
protein [56] or through blockage of the vacuolar-type ad-
enosine triphosphatase proton pumps, which increases 
the pH of microglial lysosomes, leading to decreased deg-
radation of β-amyloid [57].
An observational study using primary care patients 
over 75 years of age found that PPI use was significantly 
associated with an increased risk of any dementia (HR 
1.38) and Alzheimer disease (HR 1.44) compared to non-
use [58]. Another observational study also concluded that 
patients under regular PPI medication had a significantly 
increased risk of dementia compared to nonusers (HR 
1.44) [59]. In contrast, a recently published case-control 
study was not able to find an association between PPI use 
and risk of Alzheimer disease, and higher doses or a lon-
ger duration of use was also not associated with an in-
creased risk [60]. Reviewing Hill criteria, the current evi-
dence has a weak strength, and only temporality is pres-
ent [7]; therefore, more studies are needed to conclude 
about the effect of PPIs on dementia.
Kidney Diseases
Early since the clinical use of PPIs, isolated cases of 
acute interstitial nephritis have been attributable to PPI 
use [61], and the largest case series included only 18 cases 
[62]. The exact mechanism is still unknown, but it seems 
to be triggered by a hypersensitivity immune reaction to 
the drug or one of its metabolites [62]. This class effect is 
more commonly seen in the elderly [62]. Reviewing Hill 
criteria, the current evidence has a weak strength, and 
only temporality and experimental criteria are present 
[7].
Until recently, little was known about the impact of 
PPI use on the development of chronic kidney disease 
(CKD), and some authors proposed that PPIs can in-
duce CKD due to recurrent episodes of acute interstitial 
nephritis [63]. One large observational study found that 
patients under PPI had a 3.3% absolute risk increase of 
CKD (number needed to harm = 30), but it also report-
ed a higher incidence of hypertension, a known risk fac-
tor for CKD, in the PPI user group [63]. Another obser-
vational study based on the Healthcare database found 
that patients using PPIs had a higher risk of developing 
CKD (OR 1.29) [64], and yet another study found that 
patients under PPI had a significantly elevated risk of 
doubling of serum creatinine level (HR 1.53) and of hav-
ing a decline > 30% in estimated glomerular filtration 
rate (HR 1.32) [65]. The latter study also found that pa-
tients who used PPIs for longer durations had higher 
rates of renal adverse outcomes when compared to ≤30-
day use; however, uses over 720 days seemed to protect 
patients from CKD. This variability in the effect of PPI 
use duration on renal function raises questions regard-
ing whether a confounding factor may have influenced 
the results.
Even though these findings should draw the attention 
of the scientific community to this issue and lead to the 
development of higher-quality studies designed to assess 
the impact of PPIs on renal function, the current evidence 
is still lacking strength. The results obtained are based on 
a retrospective analysis and may have been influenced by 
unidentified confounders. Reviewing Hill criteria, the 
current evidence regarding renal failure risk in PPI users 
has a weak strength, and only temporality criteria are 
present [7].
A Best Practice Advice issued in 2017 by the American 
Gastroenterology Association recommends against rou-
tine screening/monitoring of serum creatinine in patients 
under PPIs [45].
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Conclusion
PPIs are widely used and available drugs. They were 
developed over 30 years ago, and their clinical efficiency 
made them become the first-line therapy in several clini-
cal conditions, so that they are one of the most frequent-
ly prescribed pharmacological groups all over the world.
Recently, many investigations have been published re-
garding their safety, drawing attention to previously un-
suspected adverse effects. This new evidence has alarmed 
not only the scientific community but also the general 
population. However, after reviewing the evidence pro-
duced, we understand that most studies suggesting ad-
verse effects of PPIs are of low quality, subject to many 
confounders, and lacking reproducibility, and higher-
quality studies are needed to confirm or dismiss most of 
the proposed adverse effects. 
Considering the current evidence, patients with a clear 
clinical indication for PPI treatment should probably 
benefit from the maintenance of their treatment. Never-
theless, we should not forget that some patients may be 
under PPI treatment without a clear indication and even 
that patients may be self-medicating with this over-the-
counter drug. Therefore, an effort should be made to 
withdraw the drug in those who do not require it and to 
reduce PPI use to the lowest needed dose in those requir-
ing long-term treatments. 
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